Free Trial

Fulcrum Therapeutics (FULC) Competitors

Fulcrum Therapeutics logo
$6.92 -0.02 (-0.22%)
As of 01:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FULC vs. EWTX, SDGR, BHVN, ETNB, ANIP, JANX, EVO, MESO, VERA, and OCUL

Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), Evotec (EVO), Mesoblast (MESO), Vera Therapeutics (VERA), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.

Fulcrum Therapeutics vs. Its Competitors

Fulcrum Therapeutics (NASDAQ:FULC) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Fulcrum Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

In the previous week, Edgewise Therapeutics had 17 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 19 mentions for Edgewise Therapeutics and 2 mentions for Fulcrum Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.50 beat Fulcrum Therapeutics' score of -0.32 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fulcrum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Edgewise Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fulcrum Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulcrum Therapeutics$80M4.67-$9.73M-$0.07-98.79
Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.36

Fulcrum Therapeutics currently has a consensus price target of $6.29, indicating a potential downside of 9.10%. Edgewise Therapeutics has a consensus price target of $40.00, indicating a potential upside of 208.76%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Fulcrum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulcrum Therapeutics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.50
Edgewise Therapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

Fulcrum Therapeutics' return on equity of -0.20% beat Edgewise Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fulcrum TherapeuticsN/A -0.20% -0.19%
Edgewise Therapeutics N/A -30.95%-29.45%

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Fulcrum Therapeutics beats Edgewise Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FULC vs. The Competition

MetricFulcrum TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$373.27M$2.90B$5.50B$9.01B
Dividend YieldN/A2.64%5.39%4.11%
P/E Ratio-98.7721.5027.4220.07
Price / Sales4.67282.64398.50109.13
Price / CashN/A41.4736.1356.90
Price / Book1.537.518.015.70
Net Income-$9.73M-$55.05M$3.16B$248.47M
7 Day Performance-6.30%3.05%2.08%2.92%
1 Month Performance-1.64%5.80%4.38%5.77%
1 Year Performance12.35%6.15%35.81%21.39%

Fulcrum Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FULC
Fulcrum Therapeutics
0.301 of 5 stars
$6.92
-0.2%
$6.29
-9.1%
+13.6%$373.27M$80M-98.77100
EWTX
Edgewise Therapeutics
2.6831 of 5 stars
$14.18
-0.8%
$39.78
+180.5%
-29.2%$1.50BN/A-9.1560News Coverage
Analyst Forecast
Analyst Revision
Gap Down
SDGR
Schrodinger
2.8432 of 5 stars
$20.35
-0.5%
$32.80
+61.2%
+3.1%$1.50B$207.54M-7.74790Analyst Forecast
BHVN
Biohaven
2.7996 of 5 stars
$14.44
-0.2%
$58.46
+305.0%
-56.8%$1.48BN/A-1.54239
ETNB
89BIO
1.9619 of 5 stars
$10.00
-0.8%
$26.43
+164.3%
+32.9%$1.47BN/A-2.9640
ANIP
ANI Pharmaceuticals
3.7493 of 5 stars
$66.03
+0.7%
$80.13
+21.3%
+4.1%$1.42B$614.38M-51.99600
JANX
Janux Therapeutics
1.8526 of 5 stars
$22.88
-3.1%
$95.25
+316.3%
-38.8%$1.40B$10.59M-16.8230
EVO
Evotec
1.6772 of 5 stars
$3.81
+1.3%
$5.93
+55.7%
-12.3%$1.34B$862.40M0.004,827Positive News
MESO
Mesoblast
2.1534 of 5 stars
$10.16
-2.7%
$18.00
+77.2%
+68.4%$1.33B$5.90M0.0080
VERA
Vera Therapeutics
3.6096 of 5 stars
$21.65
+3.8%
$65.00
+200.2%
-32.3%$1.33BN/A-7.2240Positive News
OCUL
Ocular Therapeutix
3.8053 of 5 stars
$8.37
+3.0%
$17.33
+107.1%
+41.6%$1.30B$63.72M-7.28230

Related Companies and Tools


This page (NASDAQ:FULC) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners